论文部分内容阅读
目的 研究卵巢肿瘤组织中ｎｍ２３Ｈ２ 基因的扩增、表达及其突变并探讨其临床意义。 方法 用免疫组织化学（ＩＨＣ） 、反转录多聚酶链反应（ＲＴＰＣＲ）和多聚酶链反应单链构象多态技术（ＰＣＲＳＳＣＰ） 方法检测４１ 例卵巢癌、２０ 例卵巢良性肿瘤和２１ 例正常卵巢组织ｎｍ２３Ｈ２ 基因的表达、扩增和突变。 结果 ①卵巢癌ｎｍ２３Ｈ２ 阳性表达率在６８ ％ 以上，显著地高于良性肿瘤及正常卵巢组织（Ｐ＜ ００１） ；②癌灶ｎｍ２３Ｈ２ 的阳性表达及扩增显著地高于转移灶（ Ｐ＜ ００１） ；③Ⅰ～Ⅱ期患者癌组织中ｎｍ２３Ｈ２ 的阳性表达率显著地高于Ⅲ～Ⅳ期者（ Ｐ＜００１） ；④ｎｍ２３Ｈ２ 的阳性表达和扩增与病理分级及病理分类无显著差异（ Ｐ＞ ００５） ；⑤ｎｍ２３Ｈ２ 阳性表达的患者近期疗效比阴性者好（ Ｐ＜ ００５）。 结论 ｎｍ２３Ｈ２ 阳性表达是卵巢恶性肿瘤的早发事件，其阳性表达的降低预示疗效差。因此，对患者进行ｎｍ２３Ｈ２ 基因的检测有助于预测预后。
Objective To study the amplification, expression and mutation of nm23H2 gene in ovarian tumor and to explore its clinical significance. Methods Immunohistochemistry (IHC), reverse transcription-polymerase chain reaction (RTPCR) and polymerase chain reaction single strand conformation polymorphism (PCRSSCP) method were used to detect 41 cases of ovarian cancer, 20 cases of benign ovarian tumors and 21 cases of normal ovarian tissue nm23 H2 gene expression, amplification and mutation. Results ① The positive expression rate of nm23H2 in ovarian cancer was over 68%, which was significantly higher than that in benign tumor and normal ovary (P <001). ② The positive expression and amplification of nm23H2 in carcinoma were significantly higher than those in metastasis (P <001). ③The positive expression rates of nm23H2 in stage Ⅰ ~ Ⅱ cancer were significantly higher than those in stage ⅢⅣ (P <001). ④ The positive expression and amplification of nm23H2 And pathological grading and pathological classification no significant difference (P> 0 05); ⑤ nm23 H2 positive expression in patients with short-term efficacy is better than negative (P <0 05). Conclusion nm23 H2 positive expression of ovarian cancer is an early event, the decrease of its positive expression predicts poor efficacy. Therefore, the detection of nm23 H2 gene in patients with prognosis.